Parexel Introduces Discussions on Diversity Research
Parexel has announced the release of “Discussions on Diversity,” an in-depth research report and interactive microsite featuring patient, academic and physician voices highlighting the importance of diversity in clinical trials. The report, issued in conjunction with International Clinical Trials Day, represents a combination of qualitative and quantitative data reflecting perspectives from respondents around the world and identifies critical barriers to achieving diversity in clinical research.
The “Discussions on Diversity” report surveyed 1,945 respondents across a broad range of racial and ethnic groups in the United States, Canada, United Kingdom, Australia, France, Hungary, Italy, Mexico, Poland and Spain. Qualitative insights were gleaned from one-on-one interviews in the United Kingdom and United States and physician focus group sessions in the United States and Canada as well as Parexel’s Patient Advisory Council meetings in the United States, Italy, Australia and the United Kingdom.
To learn more, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
